IXICO : INTERIM RESULTS ANALYST PRESENTATION

H1-22 Interim Results

24th May 2022

Giulio Cerroni	Grant Nash
CEO	CFO

Nonregulated Disclaimer

This presentation is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which includes certain information drawn from public sources does not purport to be comprehensive and has not been independently verified. It has been prepared and issued by and is the sole responsibility of the Company.

No reliance may be placed for any purpose whatsoever on the information contained in this presentation or any assumptions made as to its completeness. No representation or warranty, express or implied, is given by the Company, any of its subsidiaries or any of its advisors, directors, officers, employees or agents, as to the accuracy, reliability or completeness of the information or opinions contained in this presentation or in any revision of the presentation or of any other written or oral information made or to be made available to any information or opinions (which should not be relied upon) and no responsibility is accepted for any errors, misstatements in or omissions from this presentation or for any loss howsoever arising, directly or indirectly, from any use of this presentation or its contents. The information and opinions contained in this presentation are provided as at the date of this presentation and are subject to change without notice.

In particular, this presentation may contain certain forward-looking statements that are subject to the usual risk factors. Whilst the Company believes the expectations reflected herein to be reasonable in light of the information available to them at this time, the actual outcome may be materially different owing to factors beyond the Company's control or with in the Company's control where, for example the Company decides on a change of strategy. Accordingly no reliance may be placed on the figures or other indications contained in any such potential forward-looking statements. No representation or warranty of any kind is made with respect to the accuracy or completeness of the financial projections or other forward-looking statements, any assumptions underlying them, the future operations or the amount of any future income or loss.

The content of this presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). This presentation does not constitute or form part of any offer or invitation to see, or any solicitation of any offer to purchase or subscribe for or otherwise acquire, any securities in the Company in any jurisdiction or any other body corporation or an invitation or an inducement to engage in investment activity under section 21 of FSMA, nor shall it or any part of it form the basis of or be relied on in connection with any contract therefore. This presentation does not constitute an invitation to effect any transaction with the Company or to make use of any services provided by the Company. Reliance on the information contained in this presentation for the purposes of engaging in any investment activity may expose the investor to a significant risk of losing all of the property or assets invested. Any person who is in any doubt about the investment in business to which this presentation relates should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities.

By attending the presentation or reading or accepting this document you agree to be bound by the foregoing limitations.

IXICO plc is incorporated in England with registered number 3131723 and registered address 15 Long Lane, London, EC1A 9PN.

2

PUBLIC © IXICO plc 2022

Precision in neuroscience

AIM: IXI

Our purpose is to advance medicine and human health by delivering intelligent insights in neuroscience - differentiated with proprietary AI Analytics.

• Neurological research is the 2nd largest development area for new drugs after oncology[1].
• Dementia is the only major cause of death we can't slow down or cure[2].
• $1.3 trillion worldwide healthcare cost in 2019 of dementia[3].
• Aging population: Tripling of people with dementia to >130million between 2015 and 2050[4]
• Likelihood of a phase I clinical trial drug candidate achieving approval is just under 8% with Neurology at under 6%.[5]
• Neurological drug development timelines are amongst the longest in the industry at over 11 years

Our technology services provide data-driven insights to enable the design of more efficient clinical trials to increase the likelihood of approval of innovative, safe therapies to market, sooner.

1. PhMRA Biopharmaceutical research industry, 2016 profile [2] World dementia council, Defeating dementia: the road to 2025 [3] World Health Organisation Dementia report Sep-21[4] The World Alzheimer Report 2018, ADI, London [5] Biotechnology innovation organiszation, pharma intelligence informa, Quantitative Life Sciences: Clinical development success rates and contributing factors 2011-2020

4

PUBLIC © IXICO plc 2022

2017-2022 Growth Strategy

Focus on

Penetration

Target early

Innovate

Enhance

delivering scale

of clinical trials

phase to grow

Next generation

organic growth

and operational

market in select

into later clinical

Data platform

through

excellence

therapeutic

phases

and AI data

selective

areas

analytics

partnerships

and M&A

… to deliver sustained, double- digit profitability

5	PUBLIC © IXICO plc 2022